GERN - Geron Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.2100
-0.0200 (-1.63%)
At close: 4:00PM EDT

1.2100 0.00 (0.00%)
After hours: 6:39PM EDT

Stock chart is not supported by your current browser
Previous Close1.2300
Open1.2200
Bid1.2000 x 29200
Ask1.2000 x 39400
Day's Range1.0800 - 1.2500
52 Week Range0.9500 - 6.9900
Volume3,216,347
Avg. Volume1,879,587
Market Cap225.684M
Beta (3Y Monthly)2.37
PE Ratio (TTM)N/A
EPS (TTM)-0.1630
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.83
Trade prices are not sourced from all markets
  • Why Geron Corporation Stock Bolted Higher in the First Half of 2019
    Motley Fool9 days ago

    Why Geron Corporation Stock Bolted Higher in the First Half of 2019

    Geron's stock has rebounded nicely in the first half of 2019.

  • Such Is Life: How Geron (NASDAQ:GERN) Shareholders Saw Their Shares Drop 58%
    Simply Wall St.23 days ago

    Such Is Life: How Geron (NASDAQ:GERN) Shareholders Saw Their Shares Drop 58%

    Investing in stocks comes with the risk that the share price will fall. And there's no doubt that Geron Corporation...

  • GlobeNewswire27 days ago

    Geron Appoints Vice President, Human Resources

    Geron Corporation (GERN) today announced the appointment of Shannon Odam as Vice President, Human Resources. Ms. Odam joins other recently recruited senior leadership to further strengthen the organization as it expands its operations to support the planned opening of the Phase 3 portion of IMerge in lower risk myelodysplastic syndromes for screening and enrollment in the summer of 2019. As Vice President, Human Resources, Ms. Odam will lead all aspects of a comprehensive human resources function, including oversight of policies and operations for leadership and talent management, training, organizational development, operational effectiveness and workforce planning.

  • GlobeNewswirelast month

    Geron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress

    Updated 8-week RBC-TI rate for the Phase 2 portion of IMerge increased to 42%, from 37% in December 2018Updated 24-week RBC-TI rate for the Phase 2 portion of IMerge increased.

  • GlobeNewswirelast month

    Geron to Webcast KOL Event on June 25, 2019

    Geron Corporation (GERN) today announced that the Company will webcast an event on June 25, 2019, featuring key opinion leaders (KOLs) who are authors of imetelstat data presentations being made at the 24th Annual Congress of the European Hematology Association (EHA). The KOLs will reprise the presentations made at EHA, and Geron’s management team will provide an update regarding progress towards the Company’s 2019 objectives, including the opening of the planned Phase 3 portion of IMerge for screening and enrollment in the summer of 2019. Uwe Platzbecker, M.D., Director, Medical Department I – Hematology and Cell Therapy, University of Leipzig Medical Center, Leipzig, Germany, will review efficacy and safety data presented at EHA from the Phase 2 portion of IMerge, the ongoing Phase 2/3 clinical trial of imetelstat in patients with lower risk myelodysplastic syndromes.

  • Benzingalast month

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

    Biotech stocks staged a steady recovery last week. ASCO presentations dominated the headlines, with Iovance Biotherapeutics Inc (NASDAQ: IOVA ) and Mirati Therapeutics Inc (NASDAQ: MRTX ) among the biggest ...

  • Why Is Geron (GERN) Down 22% Since Last Earnings Report?
    Zacks2 months ago

    Why Is Geron (GERN) Down 22% Since Last Earnings Report?

    Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Geron Stock Up More Than 50% in 2019 So Far: Here's Why
    Zacks2 months ago

    Geron Stock Up More Than 50% in 2019 So Far: Here's Why

    Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.

  • Did Geron's Big Announcement Just Go Unnoticed?
    Motley Fool2 months ago

    Did Geron's Big Announcement Just Go Unnoticed?

    Geron hints at a way forward for imetelstat in myelofibrosis, but the market isn't buying it.

  • GlobeNewswire2 months ago

    Geron Announces Two Presentations on Imetelstat at Upcoming European Hematology Association Annual Congress

    Geron Corporation (GERN) today announced that two abstracts containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the 24th European Hematology Association (EHA) Annual Congress to be held in Amsterdam, the Netherlands, from June 13-16, 2019. “We appreciate the opportunity to present additional data and analyses at EHA from the ongoing imetelstat clinical trials,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer.

  • GlobeNewswire2 months ago

    Geron Provides Imetelstat Program Update

    Geron Corporation (GERN) today provided an update to its 2019 corporate objectives for the imetelstat program. “2019 is off to a good start with the imetelstat IND transfer now complete, enabling us to move forward with the planned opening of the Phase 3 clinical trial in lower risk myelodysplastic syndromes for screening and enrollment, which we continue to expect by mid-year 2019,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer. “Our new development team has refined our regulatory strategies for myelofibrosis, which we plan to discuss at an End of Phase 2 meeting with the FDA by the end of the first quarter of 2020.

  • GlobeNewswire2 months ago

    Geron Continues to Build Senior Leadership of Its Development Team

    Geron Corporation (GERN) today announced that it is continuing to build the senior leadership of its development team with the addition of a Vice President, Biometrics, and a Vice President, Manufacturing.

  • Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up
    Zacks2 months ago

    Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up

    Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.

  • Associated Press2 months ago

    Geron: 1Q Earnings Snapshot

    The Menlo Park, California-based company said it had a loss of 5 cents per share. The drugmaker posted revenue of $57,000 in the period. The company's shares closed at $1.82. A year ago, they were trading ...

  • GlobeNewswire2 months ago

    Geron Corporation Reports First Quarter 2019 Financial Results

    MENLO PARK, Calif., May 02, 2019 -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2019. As of the quarter-end, the.

  • Analysts Estimate Geron (GERN) to Report a Decline in Earnings: What to Look Out for
    Zacks2 months ago

    Analysts Estimate Geron (GERN) to Report a Decline in Earnings: What to Look Out for

    Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Can We See Significant Institutional Ownership On The Geron Corporation (NASDAQ:GERN) Share Register?
    Simply Wall St.3 months ago

    Can We See Significant Institutional Ownership On The Geron Corporation (NASDAQ:GERN) Share Register?

    A look at the shareholders of Geron Corporation (NASDAQ:GERN) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies...

  • 3 Cancer Treatment Stocks to Buy in April
    Motley Fool3 months ago

    3 Cancer Treatment Stocks to Buy in April

    These three cancer stocks have tremendous upside potential.

  • GlobeNewswire3 months ago

    Geron Expands Senior Leadership of Its Development Team

    MENLO PARK, Calif., April 18, 2019 -- Geron Corporation (Nasdaq: GERN) today announced an expansion of its development team’s senior leadership with the addition of three.

  • Benzinga3 months ago

    Geron's Blood Cancer Candidate Creates Buying Opportunity, Needham Says In Upgrade

    Geron Corporation (NASDAQ: GERN ) announced in September that  Johnson & Johnson (NYSE: JNJ )'s Janssen unit opted to terminate a collaboration and licensing agreement between the companies for imetelstat, ...

  • Reuters3 months ago

    BRIEF-China's Geron Says Controlling Shareholder Plans To Unload Up To 6 Pct Stake In The Company

    April 8 (Reuters) - Geron Co Ltd: * SAYS CONTROLLING SHAREHOLDER PLANS TO UNLOAD UP TO 6 PERCENT STAKE IN THE COMPANY WITHIN SIX MONTHS Source text in Chinese: https://bit.ly/2IiMtRX Further company coverage: ...

  • Why Is Geron (GERN) Up 27.3% Since Last Earnings Report?
    Zacks3 months ago

    Why Is Geron (GERN) Up 27.3% Since Last Earnings Report?

    Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire3 months ago

    Geron to Present at Needham Healthcare Conference

    MENLO PARK, Calif., April 02, 2019 -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to.

  • GlobeNewswire4 months ago

    Geron Appoints Two New Independent Board Members

    MENLO PARK, Calif., March 28, 2019 -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Dawn C. Bir and Elizabeth G. O’Farrell as independent members of its.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of GERN earnings conference call or presentation 7-Mar-19 9:30pm GMT

    Q4 2018 Geron Corp Earnings Call